An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions.

BACKGROUND AND PURPOSE Iron oxide-based contrast agents have been investigated as more specific MR imaging agents for central nervous system (CNS) inflammation. Ferumoxtran-10 is a virus-size nanoparticle, taken up by reactive cells, that allows visualization of the phagocytic components of CNS lesions. Ferumoxtran-10 was compared with standard gadolinium-enhanced MR images in this exploratory trial to assess its potential in evaluation of CNS lesions with inflammatory aspects, including lymphoma, multiple sclerosis (MS), acute disseminated encephalomyelitis (ADEM), and vascular lesions. METHODS Twenty-three patients with different types of intracranial "inflammatory" lesions underwent standard brain MR with and without gadolinium, followed an average of 10 days later by a ferumoxtran-10 scan. Patients were imaged 24 hours after infusion of 2.6 mg/kg ferumoxtran-10. All MR images were evaluated subjectively by 4 investigators for a difference in enhancement patterns, which could be useful in differential diagnoses. RESULTS In 5 cases, (one ADEM, 2 stroke, one cavernous venous vascular malformation, one primary central nervous lymphoma) the ferumoxtran-10 scan showed higher signal intensity, larger area of enhancement, or new enhancing areas compared with gadolinium. Most MS patients showed less enhancement with ferumoxtran-10 than with gadolinium. CONCLUSION Ferumoxtran-10 showed different enhancement patterns in a variety of CNS lesions with inflammatory components in comparison to gadolinium. The impact of timing and therapy need further evaluation to better assess ferumoxtran-10 in addition to gadolinium as contrast agents for use in diagnosis and monitoring therapy in patients with CNS inflammatory lesions.

[1]  Wei Huang,et al.  Evidence for shutter‐speed variation in CR bolus‐tracking studies of human pathology , 2005, NMR in biomedicine.

[2]  E. Neuwelt,et al.  Single-dose contrast agent for intraoperative MR imaging of intrinsic brain tumors by using ferumoxtran-10. , 2005, AJNR. American journal of neuroradiology.

[3]  X. Wu,et al.  Adult neural stem cell therapy: expansion in vitro, tracking in vivo and clinical transplantation. , 2005, Current drug targets.

[4]  E. Neuwelt,et al.  Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours , 2004, Neuropathology and applied neurobiology.

[5]  Bruno Brochet,et al.  Macrophage Imaging in Central Nervous System and in Carotid Atherosclerotic Plaque Using Ultrasmall Superparamagnetic Iron Oxide in Magnetic Resonance Imaging , 2004, Investigative radiology.

[6]  Heather Kalish,et al.  Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. , 2004, Blood.

[7]  Roland Martin,et al.  Magnetic resonance imaging of labeled T‐cells in a mouse model of multiple sclerosis , 2004, Annals of neurology.

[8]  K. Nicolay,et al.  Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. , 2004, Brain : a journal of neurology.

[9]  E. Neuwelt.  Mechanisms of Disease: The Blood-Brain Barrier , 2004, Neurosurgery.

[10]  C. Tempany,et al.  Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. , 2003, Radiology.

[11]  M. Rausch,et al.  MRI‐based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE , 2003, Magnetic resonance in medicine.

[12]  Ralph Weissleder,et al.  Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. , 2003, The New England journal of medicine.

[13]  M. E. Kooi,et al.  Accumulation of Ultrasmall Superparamagnetic Particles of Iron Oxide in Human Atherosclerotic Plaques Can Be Detected by In Vivo Magnetic Resonance Imaging , 2003, Circulation.

[14]  James I. Cohen,et al.  Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. , 2002, AJNR. American journal of neuroradiology.

[15]  B Hamm,et al.  Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles , 2001, Journal of magnetic resonance imaging : JMRI.

[16]  J K Udupa,et al.  Glatiramer acetate (Copaxone) treatment in relapsing–remitting MS , 2000, Neurology.

[17]  G J Barker,et al.  Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. , 1997, Brain : a journal of neurology.

[18]  M. Filippi,et al.  Triple dose of gadolinium-DTPA and delayed MRI in patients with benign multiple sclerosis. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[19]  R R Edelman,et al.  Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227). , 1995, AJR. American journal of roentgenology.

[20]  A. Olukotun,et al.  Phase I clinical evaluation of a new iron oxide MR contrast agent , 1994, Journal of magnetic resonance imaging : JMRI.

[21]  R. Weissleder,et al.  Delivery of virus-sized iron oxide particles to rodent CNS neurons. , 1994, Neurosurgery.

[22]  A. Elster.  Magnetic resonance contrast enhancement in cerebral infarction. , 1994, Neuroimaging clinics of North America.

[23]  A. Thompson,et al.  Major differences in the dynamics of primary and secondary progressive multiple sclerosis , 1991, Annals of neurology.

[24]  R. Weissleder,et al.  Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. , 1990, Radiology.

[25]  J. Kurhanewicz,et al.  Diffusion-weighted MR imaging of acute stroke: correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in cats. , 1990, AJNR. American journal of neuroradiology.

[26]  W. I. McDonald,et al.  Heterogeneity of blood‐brain barrier changes in multiple sclerosis , 1990, Neurology.

[27]  E. Neuwelt,et al.  Comparison of Two Superparamagnetic Viral-Sized Iron Oxide Particles Feridex and Combidex in Imaging Intracranial Tumors , 2001 .

[28]  S. Heiland,et al.  Early MR detection of experimentally induced cerebral ischemia using magnetic susceptibility contrast agents: comparison between gadopentetate dimeglumine and iron oxide particles. , 1995, AJNR. American journal of neuroradiology.

[29]  P. Jacobs,et al.  Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. , 1995, Magnetic resonance imaging.